Now, a study from researchers at Instituto Gulbenkian de Ciência and Rockefeller University has shown that fat tissue is innervated and that direct stimulation of neurons in fat is sufficient to induce fat breakdown. The team state that their results set up the stage for developing novel anti-obesity therapies. The opensource study is published in the journal Cell.
Previous studies show that fat tissue constitutes 20 to 25% of human body weight being an energy storage container, in the form of triglycerides. Twenty years ago the team identified the hormone leptin, which is produced by fat cells in amounts that are proportional to the amount of fat, and informs the brain about how much fat is available in the body. Leptin functions as an ‘adipostat’ neuro-endocrine signal that preserves body’s fat mass in a relatively narrow range of variation. Low leptin levels increase appetite and lower basal metabolism, whereas high leptin levels blunt appetite and promote fat breakdown. However, until now it was largely unknown what circuits close the neuroendocrine loop, such that leptin action in the brain signals back to the fat.
The current study combined a variety of techniques to functionally establish, for the first time, that white fat tissue is innervated. The lab dissected these nerve fibers from mouse fat, and using molecular markers identified these as sympathetic neurons. Ultra sensitive imaging was also used on the intact white fat tissue of a living mouse which showed that the fat cells can be encapsulated by these sympathetic neural terminals.
Genetically engineered mice were then used to assess the functional relevance of these fat projecting neurons. The group used optogenetics to locally activate these sympathetic neurons in fat pads of mice, and observed fat breakdown and fat mass reduction. Results show that the local activation of these neurons, leads to the release of norepinephrine, a neurotransmitter, that triggers a cascade of signals in fat cells leading to fat hydrolysis. The lab conclude that without these neurons, leptin is unable to drive fat-breakdown.
The team surmise that this result provides new hopes for treating central leptin resistance, a condition in which the brains of obese people are insensitive to leptin. They go on to add that these studies add an important new piece to the puzzle that enables leptin to induce fat loss.
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.